4-NPBA4-nonylphenylboronic acid
A boronic acid inhibiting FAAH at 9.1 nanomolar, about 870 times selective over MAGL.
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
C₁₅H₂₅BO₂
CAS 256383-45-6
- Family
- ECS pharmacological toolEnzyme inhibitor
- Molar mass
- 248.17 g/mol
Updated on
In plain terms
4-Nonylphenylboronic acid is a laboratory molecule that, in enzyme-inhibition tests, blocks the enzyme that destroys anandamide, the cannabinoid made by the body. It was picked out in 2008 from among chemical compounds sold commercially. It serves as a research tool; no study in humans was found.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to 4-NPBA: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of 4-NPBA.
FAAHFAAH found in 7 regions of the body
- CortexpresentCortical pyramidal neurons1
- Basal gangliapresentStriatal neurons1
- HypothalamuspresentPresent in hypothalamic nuclei1
- CerebellumpresentPurkinje cells and cerebellar layers1
- BrainstempresentInferior olivary nuclei1
- Adipose tissuepresentExpressed in mature adipocytes2
- BonepresentPresent on osteoclasts3
Map sources
- Romero J et al. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res Mol Brain Res, 2002 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Rossi F et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone, 2009 (new tab)
Cited values
- FAAHInhibitorIC50 = 9.1 nM67 out of 100
Minkkilä et al., J Med Chem 2008 (new tab) · enzymatic inhibition of FAAH (abstract: 0.0091 µM); preparation and species not specified in the abstract; selectivity of about 870-fold over MGL
- MAGLInhibitorIC50 = 7.9 µM18 out of 100
Minkkilä et al., J Med Chem 2008 (new tab) · enzymatic inhibition of MGL (abstract: 7.9 µM); preparation and species not specified in the abstract
Pharmacology
4-Nonylphenylboronic acid is a FAAH inhibitor described in 2008 by Minkkilä and colleagues. Their work evaluated a series of commercial boronic acids on FAAH and MGL: the compounds were generally selective for FAAH, with IC50 values in the nanomolar or low-micromolar range, and eight of them also inhibited MGL in the micromolar range. The most potent is the phenylboronic acid bearing a nonyl group at the para position, with an IC50 of 9.1 nM on FAAH and 7.9 µM on MGL, a selectivity of about 870-fold. The abstract of the article does not specify the mechanism of inhibition or the enzyme preparations used. No data in whole animals or in humans were found.
History
- Source
- An entirely synthetic compound; no natural occurrence was found in the sources consulted. The 2008 study screened commercial boronic acids, so the compound existed as a catalogue product before being evaluated as a FAAH inhibitor (Minkkilä et al. 2008).
Origin
Research tool
No biological pathway: 4-nonylphenylboronic acid is a synthetic compound (an arylboronic acid with a nonyl chain), unrelated to the plant cannabinoid pathway from CBGA.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found.
- France
Not classified: 4-nonylphenylboronic acid is not on the ANSM consolidated list of narcotics (updated 16/02/2026) and this arylboronic acid falls within none of the generic families of that list. No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Enzyme inhibitor
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
4-Nonylphenylboronic acid (new tab)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
Identifiers
Names
- Common name
- 4-nonylphenylboronic acid
- IUPAC name
- (4-nonylphenyl)boronic acid
- Other names
- 4-NPBA
Identifiers
- Formula
- C₁₅H₂₅BO₂
- CAS
- 256383-45-6
- PubChem CID
- 4589192(new tab)
- InChIKey
- VONVJOGSLHAKOX-UHFFFAOYSA-N
- SMILES
- B(C1=
CC= C(C= C1) CCCCCCCCC) (O) O
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.